Emyria Ltd has released a press release.
Recruitment commenced for EMD-RX5 Phase 1 Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Ethics approval received for EMD-RX5 Phase 1 Study
- Emyria grows its novel MDMA-analogue library
- Application for quotation of securities - EMD
- Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
- Notification regarding unquoted securities - EMD
Later from Emyria
- Emyria launches second ultra-pure CBD capsule
- Broker Briefing Presentation
- Further positive MDMA analogue screening results received
- EMD-RX5 demonstrates excellent safety and bioavailability
- Emyria expands MDMA analogue program with UWA
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria